Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ValiRx had entered into an agreement with Kalos Therapeutics, whereby ValiRx would perform a range of preclinical evaluation experiments to determine whether to enter a full licensing agreement for KTH222.
Lead Product(s): KTH222
Therapeutic Area: Oncology Product Name: KTH222
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: ValiRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination May 27, 2021
Details:
Under the terms of the agreement, ValiRx has the right to perform a defined series of preclinical, cell-based assays to consider the benefit of using KTH222 in combination with standard of care treatment, Paclitaxel.
Lead Product(s): KTH222
Therapeutic Area: Oncology Product Name: KTH222
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: ValiRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 10, 2020
Details:
Kalos has identified numerous immune-stimulating agents and will target two based on safety and efficacy, as well as other desirable attributes, to begin development.
Lead Product(s): KTH-222
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2020
Details:
In 2019, Kalos Therapeutics signed a Letter of Intent with Oncology Pharma, for a worldwide license and co-development of Kalos's lead anti-cancer drug, KTH-222.
Lead Product(s): KTH-222
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: Oncology Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 06, 2020